Manufacturing replacement ventricles to treat heart disease

Get Involved

Manufacturing replacement ventricles to treat heart disease

Get Involved

Where collaborative science fuels transformative research

MaVen’s Network Spans Across Collaborating Institutions.

We are grateful for the support of our network and our home institution – the University Health Network (UHN) McEwen Stem Cell Institute.

MaVen’s Network Spans Across Collaborating Institutions.

We are grateful for the support of our network and our home institution – the University Health Network (UHN) McEwen Stem Cell Institute.

MaVen’s Network Spans Across Collaborating Institutions.

We are grateful for the support of our network and our home institution – the University Health Network (UHN) McEwen Stem Cell Institute.

Principal Investigators

Supported by the Government of Canada’s New Frontiers in Research Fund, MaVen brings together 22 Principal Investigators from 10 different institutions. A highly interdisciplinary approach is our key to making a big impact in high-risk, high-reward areas of research.

Principal Investigators

Stem Cell-Driven Cardiac Innovation

A journey through the science shaping tomorrow’s medicine.

Our Three Major Deliverables

01 CARDIAC MICROTISSUES

Can we establish scalable, economic methods for manufacturing stem-cell derived cardiac tissues for non-invasive delivery to injured myocardium?

02 ENHANCED CARDIOMYOCYTES

Can we exploit recent advances in synthetic biology and gene-editing to engineer stem-cell derived cardiomyocytes that will survive better post-transplantation?

03 BIOPRINTED VENTRICULAR PUMP

Can we ultimately advance from delivery of cardiac cells to replacement of the failing organ itself?

01 CARDIAC MICROTISSUES

Can we establish scalable, economic methods for manufacturing stem-cell derived cardiac tissues for non-invasive delivery to injured myocardium?

02 ENHANCED CARDIOMYOCYTES

Can we exploit recent advances in synthetic biology and gene-editing to engineer stem-cell derived cardiomyocytes that will survive better post-transplantation?

03 BIOPRINTED VENTRICULAR PUMP

Can we ultimately advance from delivery of cardiac cells to replacement of the failing organ itself?

01 CARDIAC MICROTISSUES

Can we establish scalable, economic methods for manufacturing stem-cell derived cardiac tissues for non-invasive delivery to injured myocardium?

02 ENHANCED CARDIOMYOCYTES

Can we exploit recent advances in synthetic biology and gene-editing to engineer stem-cell derived cardiomyocytes that will survive better post-transplantation?

03 BIOPRINTED VENTRICULAR PUMP

Can we ultimately advance from delivery of cardiac cells to replacement of the failing organ itself?

01 CARDIAC MICROTISSUES

Can we establish scalable, economic methods for manufacturing stem-cell derived cardiac tissues for non-invasive delivery to injured myocardium?

02 ENHANCED CARDIOMYOCYTES

Can we exploit recent advances in synthetic biology and gene-editing to engineer stem-cell derived cardiomyocytes that will survive better post-transplantation?

03 BIOPRINTED VENTRICULAR PUMP

Can we ultimately advance from delivery of cardiac cells to replacement of the failing organ itself?

01 CARDIAC MICROTISSUES

Can we establish scalable, economic methods for manufacturing stem-cell derived cardiac tissues for non-invasive delivery to injured myocardium?

02 ENHANCED CARDIOMYOCYTES

Can we exploit recent advances in synthetic biology and gene-editing to engineer stem-cell derived cardiomyocytes that will survive better post-transplantation?

03 BIOPRINTED VENTRICULAR PUMP

Can we ultimately advance from delivery of cardiac cells to replacement of the failing organ itself?

01 CARDIAC MICROTISSUES

Can we establish scalable, economic methods for manufacturing stem-cell derived cardiac tissues for non-invasive delivery to injured myocardium?

02 ENHANCED CARDIOMYOCYTES

Can we exploit recent advances in synthetic biology and gene-editing to engineer stem-cell derived cardiomyocytes that will survive better post-transplantation?

03 BIOPRINTED VENTRICULAR PUMP

Can we ultimately advance from delivery of cardiac cells to replacement of the failing organ itself?

01 CARDIAC MICROTISSUES

Can we establish scalable, economic methods for manufacturing stem-cell derived cardiac tissues for non-invasive delivery to injured myocardium?

02 ENHANCED CARDIOMYOCYTES

Can we exploit recent advances in synthetic biology and gene-editing to engineer stem-cell derived cardiomyocytes that will survive better post-transplantation?

03 BIOPRINTED VENTRICULAR PUMP

Can we ultimately advance from delivery of cardiac cells to replacement of the failing organ itself?

01 CARDIAC MICROTISSUES

Can we establish scalable, economic methods for manufacturing stem-cell derived cardiac tissues for non-invasive delivery to injured myocardium?

02 ENHANCED CARDIOMYOCYTES

Can we exploit recent advances in synthetic biology and gene-editing to engineer stem-cell derived cardiomyocytes that will survive better post-transplantation?

03 BIOPRINTED VENTRICULAR PUMP

Can we ultimately advance from delivery of cardiac cells to replacement of the failing organ itself?

01 CARDIAC MICROTISSUES

Can we establish scalable, economic methods for manufacturing stem-cell derived cardiac tissues for non-invasive delivery to injured myocardium?

02 ENHANCED CARDIOMYOCYTES

Can we exploit recent advances in synthetic biology and gene-editing to engineer stem-cell derived cardiomyocytes that will survive better post-transplantation?

03 BIOPRINTED VENTRICULAR PUMP

Can we ultimately advance from delivery of cardiac cells to replacement of the failing organ itself?

Science starts with people.

At the core of these cutting-edge stem cell-based cardiac therapies is the collaborative effort of an interdisciplinary team of researchers from around the globe.

Meet the Team